The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
SGLT2 Inhibitors and the Diabetic Kidney
Open accessAbstract
Diabetic nephropathy (DN) is the most common cause of end-stage renal disease worldwide. Blood glucose and blood pressure control reduce the risk of developing this complication; however, once DN is established, it is only possible to slow progression. Sodium–glucose cotransporter 2 (SGLT2) inhibitors, the most recent glucose-lowering oral agents, may have the potential to exert nephroprotection not only through improving glycemic control but also through glucose-independent effects, such as blood pressure–lowering and direct renal effects. It is important to consider, however, that in patients with impaired renal function, given their mode of action, SGLT2 inhibitors are less effective in lowering blood glucose. In patients with high cardiovascular risk, the SGLT2 inhibitor empagliflozin lowered the rate of cardiovascular events, especially cardiovascular death, and substantially reduced important renal outcomes. Such benefits on DN could derive from effects beyond glycemia. Glomerular hyperfiltration is a potential risk factor for DN. In addition to the activation of the renin-angiotensin-aldosterone system, renal tubular factors, including SGLT2, contribute to glomerular hyperfiltration in diabetes. SGLT2 inhibitors reduce sodium reabsorption in the proximal tubule, causing, through tubuloglomerular feedback, afferent arteriole vasoconstriction and reduction in hyperfiltration. Experimental studies showed that SGLT2 inhibitors reduced hyperfiltration and decreased inflammatory and fibrotic responses of proximal tubular cells. SGLT2 inhibitors reduced glomerular hyperfiltration in patients with type 1 diabetes, and in patients with type 2 diabetes, they caused transient acute reductions in glomerular filtration rate, followed by a progressive recovery and stabilization of renal function. Interestingly, recent studies consistently demonstrated a reduction in albuminuria. Although these data are promising, only dedicated renal outcome trials will clarify whether SGLT2 inhibitors, in addition to their glycemic and blood pressure benefits, may provide nephroprotective effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
New Insights into Epithelial-Mesenchymal Transition in Kidney Fibrosis
Liu, Y. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008121226 · Cited by 870
Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 777
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Kohan, D. E., Fioretto, P., Tang, W., & List, J. F. (2014) · Kidney International · doi:10.1038/ki.2013.356 · Cited by 652
Self-citationFollow-up of blood-pressure lowering and glucose control in type 2 diabetes
Zoungas, S., Chalmers, J., Neal, B., Billot, L., Li, Q., Hirakawa, Y., Arima, H., Monaghan, H., Joshi, R., Colagiuri, S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407963 · Cited by 626
Hemodynamically mediated glomerular injury and the progressive nature of kidney disease
Brenner, P. D. B. M. (1983) · Kidney International · doi:10.1038/ki.1983.72 · Cited by 614
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Nelson, R. G., Bennett, P. H., Beck, G. J., Tan, M., Knowler, W. C., Mitch, W. E., Hirschman, G. H., & Myers, B. D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199611283352203 · Cited by 477
Histopathology of Diabetic Nephropathy
Fioretto, P., & Mauer, M. (2007) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2007.01.012 · Cited by 467
Self-citationPatterns of renal injury in NIDDM patients with microalbuminuria
Fioretto, P., Mauer, M., Brocco, E., Velussi, M., Frigato, F., Muollo, B., Sambataro, M., Abaterusso, C., Baggio, B., Crepaldi, G., et al. (1996) · Diabetologia · doi:10.1007/s001250050616 · Cited by 410
Self-citationVallon, V., Rose, M., Gerasimova, M., Satriano, J., Platt, K. A., Koepsell, H., Cunard, R., Sharma, K., Thomson, S. C., & Rieg, T. (2013) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00409.2012 · Cited by 370
Glomerular Hyperfiltration in Experimental Diabetes Mellitus: Potential Role of Tubular Reabsorption
VALLON, V., RICHTER, K., BLANTZ, R. C., THOMSON, S., & OSSWALD, H. (1999) · Journal of the American Society of Nephrology · doi:10.1681/asn.v10122569 · Cited by 356
Magee, G. M., Bilous, R. W., Cardwell, C. R., Hunter, S. J., Kee, F., & Fogarty, D. G. (2009) · Diabetologia · doi:10.1007/s00125-009-1268-0 · Cited by 345
Terami, N., Ogawa, D., Tachibana, H., Hatanaka, T., Wada, J., Nakatsuka, A., Eguchi, J., Horiguchi, C. S., Nishii, N., Yamada, H., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100777 · Cited by 341
Neal, B., Perkovic, V., de Zeeuw, D., Mahaffey, K. W., Fulcher, G., Stein, P., Desai, M., Shaw, W., Jiang, J., Vercruysse, F., et al. (2013) · American Heart Journal · doi:10.1016/j.ahj.2013.05.007 · Cited by 341
Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes
Ruggenenti, P., Porrini, E. L., Gaspari, F., Motterlini, N., Cannata, A., Carrara, F., Cella, C., Ferrari, S., Stucchi, N., Parvanova, A., et al. (2012) · Diabetes Care · doi:10.2337/dc11-2189 · Cited by 321
Thomson, S. C., Rieg, T., Miracle, C., Mansoury, H., Whaley, J., Vallon, V., & Singh, P. (2012) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00357.2011 · Cited by 315
DeFronzo, R. A., Hompesch, M., Kasichayanula, S., Liu, X., Hong, Y., Pfister, M., Morrow, L. A., Leslie, B. R., Boulton, D. W., Ching, A., et al. (2013) · Diabetes Care · doi:10.2337/dc13-0387 · Cited by 293
Panchapakesan, U., Pegg, K., Gross, S., Komala, M. G., Mudaliar, H., Forbes, J., Pollock, C., & Mather, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054442 · Cited by 277
Yale, J. ‐., Bakris, G., Cariou, B., Nieto, J., David‐Neto, E., Yue, D., Wajs, E., Figueroa, K., Jiang, J., Law, G., et al. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12348 · Cited by 273
Kidney function in early diabetes: the tubular hypothesis of glomerular filtration
Thomson, S. C., Vallon, V., & Blantz, R. C. (2004) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00208.2003 · Cited by 244
The pathogenic role of the renal proximal tubular cell in diabetic nephropathy
Tang, S. C. W., & Lai, K. N. (2012) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfs260 · Cited by 207
Freitas, H. S., Anhê, G. F., Melo, K. F. S., Okamoto, M. M., Oliveira-Souza, M., Bordin, S., & Machado, U. F. (2008) · Endocrinology · doi:10.1210/en.2007-1088 · Cited by 192
Gembardt, F., Bartaun, C., Jarzebska, N., Mayoux, E., Todorov, V. T., Hohenstein, B., & Hugo, C. (2014) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00145.2014 · Cited by 189
De Nicola, L., Gabbai, F. B., Liberti, M. E., Sagliocca, A., Conte, G., & Minutolo, R. (2014) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2014.02.010 · Cited by 167
Škrtić, M., Yang, G. K., Perkins, B. A., Soleymanlou, N., Lytvyn, Y., von Eynatten, M., Woerle, H. J., Johansen, O. E., Broedl, U. C., Hach, T., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3396-4 · Cited by 159
Škrtić, M., & Cherney, D. Z. I. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000084 · Cited by 156
Glomerulotubular Balance, Tubuloglomerular Feedback, and Salt Homeostasis
Thomson, S. C., & Blantz, R. C. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007121326 · Cited by 116
Residual microvascular risk in diabetes: unmet needs and future directions
Fioretto, P., Dodson, P. M., Ziegler, D., & Rosenson, R. S. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.213 · Cited by 115
Self-citationGilbert, R. E. (2013) · Kidney International · doi:10.1038/ki.2013.451 · Cited by 112
Phlorizin Prevents Glomerular Hyperfiltration but not Hypertrophy in Diabetic Rats
Malatiali, S. A., Francis, I. M., & Barac‐Nieto, M. (2008) · Journal of Diabetes Research · doi:10.1155/2008/305403 · Cited by 104
Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes
Hannedouche, T. P., Delgado, A. G., Gnionsahe, D. A., Boîtard, C., Lacour, B., & Grünfeld, J. (1990) · Kidney International · doi:10.1038/ki.1990.95 · Cited by 104
Lack of A1 Adenosine Receptors Augments Diabetic Hyperfiltration and Glomerular Injury
Faulhaber‐Walter, R., Chen, L., Oppermann, M., Kim, S. M., Huang, Y. G., Hiramatsu, N., Mizel, D. E., Kajiyama, H., Zerfas, P. M., Briggs, J. P., et al. (2008) · Journal of the American Society of Nephrology · doi:10.1681/asn.2007060721 · Cited by 90
Ferrannini, E., Veltkamp, S. A., Smulders, R. A., & Kadokura, T. (2013) · Diabetes Care · doi:10.2337/dc12-1503 · Cited by 81
The effect of dapagliflozin on renal function in patients with type 2 diabetes
Kohan, D. E., Fioretto, P., Johnsson, K. M., Parikh, S. J., Ptaszynska, A., & Ying, L. (2016) · Journal of Nephrology · doi:10.1007/s40620-016-0261-1 · Cited by 79
Self-citationKomala, M. G., Gross, S., Mudaliar, H., Huang, C., Pegg, K., Mather, A., Shen, S., Pollock, C. A., & Panchapakesan, U. (2014) · PLoS ONE · doi:10.1371/journal.pone.0108994 · Cited by 70
The effects of GLP-1 analogues, DPP-4 inhibitors and SGLT2 inhibitors on the renal system
Schernthaner, G., Mogensen, C. E., & Schernthaner, G.-H. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114542802 · Cited by 66
Sodium glucose cotransporter 2 and the diabetic kidney
Komala, M. G., Panchapakesan, U., Pollock, C. A., & Mather, A. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e32835a17ae · Cited by 60
Are SGLT2 Inhibitors Reasonable Antihypertensive Drugs and Renoprotective?
Lovshin, J. A., & Gilbert, R. E. (2015) · Current Hypertension Reports · doi:10.1007/s11906-015-0551-3 · Cited by 36
Renal sodium metabolism in relation to hypertension in diabetes.
Ditzel, J., Lervang, H. H., & Brøchner‐Mortensen, J. (1989) · PubMed · Cited by 19
Cited by
Mosenzon, O., Wiviott, S. D., Cahn, A., Rozenberg, A., Yanuv, I., Goodrich, E. L., Murphy, S. A., Heerspink, H. J. L., Zelniker, T. A., Dwyer, J. P., et al. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30180-9 · Cited by 684
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
Li, C., Zhang, J., Xue, M., Li, X., Han, F., Liu, X., Xu, L., Lu, Y., Cheng, Y., Li, T., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0816-2 · Cited by 580
Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities
Opazo-Ríos, L., Mas, S., Marín-Royo, G., Mezzano, S., Gómez-Guerrero, C., Moreno, J. A., & Egido, J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21072632 · Cited by 363
Packer, M., Anker, S. D., Butler, J., Filippatos, G., & Zannad, F. (2017) · JAMA Cardiology · doi:10.1001/jamacardio.2017.2275 · Cited by 336
Metadata
- Authors
- Fioretto, P., Zambon, A., Rossato, M., Busetto, L., & Vettor, R.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-07-16
- Volume
- 39
- Issue
- Supplement_2
- Pages
- S165-S171
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2500767839
- Cited by
- 348
- References
- 49
- FWCI
- 27.14
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.